Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cinacalcet added to standard of care in young children with dialysis-dependent chronic kidney disease and secondary hyperparathyroidism
2011-004618-40Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cinacalcet in secondary hyperparathyroidism (SHPT), sponsored by Amgen. Primary endpoint: Occurrence of low corrected serum calcium during the study. Started Feb 2012; status: completed.
02
Drugs
cinacalcet
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on 2011-004618-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004618-40.